Fundraising Fox
Pathos
Chicago, US · Founded 2020 · 4 known investors
Find your way into Pathos
Each arrow is one introduction. Sign up to fill in the first one.
Ask Adam Seabrook to introduce you to Matthew De Silva
You →Adam · together at Notable Labs →Matthew
Ask Jamie Chen to introduce you to Eric Schadt
You →Jamie · together at Rosetta Inpharmatics →Eric
Ask Sam Okafor to introduce you to Alex Dolan
You →Sam · together at Pathos →Alex
- Ryan Fukushima276 people can intro you
- Iker Huerga271 people can intro you
- Eric Lefkofsky266 people can intro you
Sign up to find every way you can get introduced to Pathos
- Your email: who you already know at Pathos, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Pathos team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Pathos applies AI, biological modeling, and a large collection of multimodal oncology patient data to develop cancer drugs and accelerate clinical development. It operates the PathOS platform with engines for asset selection, clinical trial execution, and an oncology foundation model.
Founders & leadership
Pathos was founded in 2020 by Eric Lefkofky, Eric Lefkofsky, and Ryan Fukushima.
Board
Investors · 4
How we know: Lightbank's portfolio page · Not right? Tell us
How we know: New Enterprise Associates (NEA)'s portfolio page · a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$365M disclosed across 3 rounds · 2023–2025
▶$283MraisedMay 2025 · 11 investors · BiotechnologyRule 506(b)
- Ryan FukushimaExecutive Officer, Director
- Mohamad MakhzoumiDirector
- Alex DolanExecutive Officer
- Andrew HeinleinExecutive Officer
- Tyrell RiversDirector
- Amit MehtaDirector
- Eric LefkofkyExecutive Officer, Director
- Offering amount
- $400M
- Amount sold
- $283M
- First sale
- Apr 2025
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$62MraisedNov 2024 · 13 investors · BiotechnologyRule 506(b)
- Eric LefkofkyExecutive Officer, Director
- Amit MehtaDirector
- Ryan FukushimaExecutive Officer, Director
- Andrew HeinleinExecutive Officer
- Mohamad MakhzoumiDirector
- Alex DolanExecutive Officer
- Offering amount
- $62M
- Amount sold
- $62M
- First sale
- Oct 2024
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
▶$20MraisedMar 2023 · 4 investors · BiotechnologyRule 506(b)
- Ryan FukushimaExecutive Officer, Director
- Eric LefkofskyExecutive Officer, Director
- Offering amount
- $40M
- Amount sold
- $20M
- First sale
- Feb 2023
- Incorporated
- Corporation, Delaware, 2020
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Founder mafia
4 people who came through Pathos went on to found or lead other companies.
Frequently asked questions
- What does Pathos do?
- Pathos applies AI, biological modeling, and a large collection of multimodal oncology patient data to develop cancer drugs and accelerate clinical development. It operates the PathOS platform with engines for asset selection, clinical trial execution, and an oncology foundation model.
- Who founded Pathos?
- Pathos was founded by Eric Lefkofky, Eric Lefkofsky, Ryan Fukushima in 2020.
- Who are Pathos's investors?
- Pathos's investors include Cota Capital, Lightbank, Lingotto, New Enterprise Associates (NEA).
- How much funding has Pathos raised?
- Pathos has disclosed $365M raised across 3 rounds.
- Where is Pathos headquartered?
- Pathos is headquartered in Chicago, US.